Modified Herpes Virus as a Weapon Against Skin Cancer? A new study suggests it might work—even for metastases deep within the ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) saw its stock soar by 200% following the announcement of a remarkable cancer remission ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE ...

Investing.com -- MiNK Therapeutics, Inc. (NASDAQ: INKT) stock soared 200% after the company announced a complete remission in a patient with metastatic testicular cancer following treatment with its ...

Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery87% of ...

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Patients were treated with a genetically modified HSV-1 in combination with an immunotherapy (nivolumab). By the end of the ...